Esperion Therapeutics ESPR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$105.83M-1.7% | -$104.02M+32.1% | -$153.22M-196% | ||
| $106K+1.0% | $105K-0.9% | $106K0.0% | $106K+19.1% | $89K+41.3% | ||
| $9.91M+0.4% | $9.87M-4.1% | $10.29M-6.1% | $10.96M-2.3% | $11.22M-6.4% | ||
| $2.9M-3.7% | $3.01M+18.5% | $2.54M+18.7% | $2.14M+21.5% | $1.76M+17.5% | ||
| $51.06M-15.0% | $60.05M+17.4% | $51.16M+8.0% | $47.39M+77.6% | $26.68M-15.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $42.67M— | —— | —— | ||
| $27.29M-12.6% | $31.22M+25.6% | $24.85M+49.3% | $16.65M-14.8% | $19.53M+6.5% | ||
| $43.21M+40.3% | $30.8M+20.4% | $25.59M+9.6% | $23.35M+86.0% | $12.55M-11.7% | ||
| $38.99M+50.2% | $25.96M+66.4% | $15.6M+851% | $1.64M+107% | -$24.81M-46.9% | ||
| —— | —— | -$93.29M— | —— | —— | ||
| $189K— | $0— | $0-100% | $167K-31.6% | $244K-23.0% | ||
| -$189K— | $0— | $0+100% | -$167K+31.6% | -$244K+23.0% | ||
| —— | $0-100% | $24.93M-50.0% | $49.86M-33.3% | $74.79M-25.0% | ||
| —— | $244K+28.3% | $190.25K+39.4% | $136.5K+65.0% | $82.75K+185% | ||
| $59.9M+65.5% | $36.18M-11.8% | $41.02M— | —— | —— | ||
| $41.53M+79.8% | $23.09M+144% | -$52.27M— | —— | —— | ||
| —— | $16.27M+8.2% | $15.04M+8.9% | $13.81M+9.8% | $12.58M+10.8% | ||
| —— | $612K+33.3% | $459K+50.0% | $306K+100% | $153K— | ||
| $2.9M-3.7% | $3.01M+18.5% | $2.54M+18.7% | $2.14M+21.5% | $1.76M+17.5% | ||
| $106K+1.0% | $105K-0.9% | $106K0.0% | $106K+19.1% | $89K+41.3% | ||
| —— | —— | —— | —— | —— | ||
| $27.29M-12.6% | $31.22M+25.6% | $24.85M+49.3% | $16.65M-14.8% | $19.53M+6.5% | ||
| $43.21M+40.3% | $30.8M+20.4% | $25.59M+9.6% | $23.35M+86.0% | $12.55M-11.7% | ||
| $58.02M+1.4% | $57.21M+6.6% | $53.67M+5.2% | $51.02M+35.2% | $37.75M+53.1% | ||
| $63.06M+14.5% | $55.06M+9.9% | $50.11M+17.6% | $42.61M+16.5% | $36.56M+40.2% | ||
| —— | —— | —— | —— | $7.5M— | ||
| —— | $72.6M-5.9% | $77.12M-5.5% | $81.63M-5.2% | $86.15M-5.0% | ||
| —— | $0-100% | $24.93M-50.0% | $49.86M-33.3% | $74.79M-25.0% | ||
| —— | $244K+28.3% | $190.25K+39.4% | $136.5K+65.0% | $82.75K+185% | ||
| $26.57M+157% | $10.35M— | —— | —— | —— | ||
| —— | $54.91M-41.4% | $93.71M-29.3% | $132.5M-22.6% | $171.29M-18.5% | ||
| —— | $612K+33.3% | $459K+50.0% | $306K+100% | $153K— | ||
| —— | —— | —— | —— | $60K-41.2% | ||
| —— | —— | -$93.29M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Esperion Therapeutics generate?
- Esperion Therapeutics (ESPR) generated -$86.1M in operating cash flow over the trailing twelve months.
- What is Esperion Therapeutics's free cash flow?
- After $189.0K of capital expenditures, Esperion Therapeutics's free cash flow was -$86.2M over the trailing twelve months, down 129.5% year over year.
- Where does Esperion Therapeutics's cash flow data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
